Ruth Fernandez-Ruiz

Rheumatology

535 E 70th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Journal: Lancet (London, England)

Published: September 18, 2025

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study.

Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study.

Journal: Lupus science & medicine

Published: June 12, 2025

Erratum to "2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective" [The Journal of Arthroplasty 38 (2023) 2193-2201].

Erratum to "2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective" [The Journal of Arthroplasty 38 (2023) 2193-2201].

Journal: The Journal of arthroplasty

Published: December 04, 2023

Advances in the management of systemic lupus erythematosus.

Advances in the management of systemic lupus erythematosus.

Journal: BMJ (Clinical research ed.)

Published: October 26, 2023

Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.

Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.

Journal: The Journal of rheumatology

Published: March 21, 2023

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

Journal: Arthritis care & research

Published: March 10, 2023

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

Journal: The Journal of arthroplasty

Published: March 10, 2023

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 10, 2023

Supporting International Medical Graduates in Rheumatology: A Call to Action.

Supporting International Medical Graduates in Rheumatology: A Call to Action.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 23, 2022

Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19.

Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19.

Journal: medRxiv : the preprint server for health sciences

Published: November 09, 2021

The role of anticomplement therapy in lupus nephritis.

The role of anticomplement therapy in lupus nephritis.

Journal: Translational research : the journal of laboratory and clinical medicine

Published: November 05, 2021

Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19.

Interferon pathway lupus risk alleles modulate risk of death from acute COVID-19.

Journal: Translational research : the journal of laboratory and clinical medicine

Published: November 02, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026